IOVANCE BIOTHERAPEUTICS, INC. 4

Interim CEO & General Counsel Frederick G. Vogt had RSUs vest into 15,626 Iovance Biotherapeutics common shares and 6,638 shares withheld for taxes, increasing his direct holdings to 595,447 shares and 93,756 remaining RSUs.

On September 8, 2026, Interim CEO & General Counsel Frederick G. Vogt of Iovance Biotherapeutics, Inc. had 15,626 restricted stock units vest, resulting in an equivalent number of common shares being issued, while 6,638 shares of common stock were simultaneously withheld by the issuer at an implied price of $8.70 per share to satisfy mandatory tax withholding obligations; these were coded as a Form 4 transaction type “F” and are not open-market sales. Following these routine equity compensation events, Vogt directly owned 595,447 shares of common stock and 93,756 remaining RSUs from the March 5, 2025 grant, with the residual RSUs set to vest in equal quarterly installments, indicating an ongoing alignment of his compensation with shareholder interests rather than discretionary buying or selling.

Filing Facts

CIK

1425205

Ticker

IOVA

Form

4

Source Type

fda

Accession

0001104659-26-106752

Alert Tier

5